-
Innovation Ranking
NewInnovation Ranking – Opiant Pharmaceuticals Inc
Opiant Pharmaceuticals Inc (Opiant), formerly, Lightlake Therapeutics Inc is a specialty pharmaceutical company that develops pharmacological treatments for substance use, addiction, and eating disorders. It focuses on developing treatments to reverse opioid overdoses, alcohol use disorder, acute cannabinoid overdose, and opioid use disorder. The company develops products based on its patented novel opioid antagonist nasal delivery technology. Opiant developed NARCAN (naloxone hydrochloride) nasal spray, a treatment to reverse opioid overdose. The product is approved for marketing in the US by...
-
Product Insights
NewNet Present Value Model: Opiant Pharmaceuticals Inc’s Nalmefene
Empower your strategies with our Net Present Value Model: Opiant Pharmaceuticals Inc's Nalmefene report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Transmucosal Drug Delivery Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Transmucosal Drug Delivery Pipeline Market Report Overview A Transmucosal drug delivery device is intended for the localized delivery of medications through a mucous membrane. The transmucosal drug delivery pipeline market research report provides comprehensive information about the transmucosal drug delivery pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. Key Segment ·      Nasal ·      Vaginal ·      Buccal Delivery ·      Rectal Key Territories ·      The US...
-
Company Profile
Opiant Pharmaceuticals Inc – Company Profile
Opiant Pharmaceuticals Inc (Opiant), formerly, Lightlake Therapeutics Inc is a specialty pharmaceutical company that develops pharmacological treatments for substance use, addiction, and eating disorders. It focuses on developing treatments to reverse opioid overdoses, alcohol use disorder, acute cannabinoid overdose, and opioid use disorder. The company develops products based on its patented novel opioid antagonist nasal delivery technology. Opiant developed NARCAN (naloxone hydrochloride) nasal spray, a treatment to reverse opioid overdose. The product is approved for marketing in the US by...
Add to Basket -
Product Insights
Net Present Value Model: Nalmefene
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Nalmefene Drug Details Nalmefene (OPNT-003) is...
-
Product Insights
Net Present Value Model: Naltrexone hydrochloride
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Naltrexone hydrochloride Drug Details Naltrexone hydrochloride...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – nalmefene
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry nalmefene Drug Details Nalmefene (OX-125) is under development for the treatment of opioid overdose....
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – naltrexone hydrochloride
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry naltrexone hydrochloride Drug Details IRT-103 (Lodonal) is under development for the treatment of patients...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – nalmefene
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry nalmefene Drug Details Nalmefene (OPNT-003) is under development for the treatment of opioid overdose....
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – naltrexone hydrochloride
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry naltrexone hydrochloride Drug Details Naltrexone hydrochloride (OPNT-002) is under development for the treatment of...